BioSpace News Archive

Drug Development

Bristol-Myers Squibb Announces Final Results from CheckMate -227 Part 1 Demonstrating Superior Overall Survival for Opdivo (nivolumab) Plus Low-Dose Yervoy (ipilimumab) vs. Chemotherapy in Advanced Non-Small Cell Lung Cancer

Opdivo plus low-dose Yervoy combination demonstrated long-term survival for patients with advanced non-small cell lung cancer across PD-L1 expression levels

September 28, 2019
·
36 min read
Biotech Bay

New Data Demonstrate Strong Outcomes for Abbott Device to Repair Leaky Tricuspid Heart Valves

New data presented at TCT 2019 on Abbott’s TriClip device from the TRILUMINATE Feasibility Study met both the primary safety and performance endpoints

September 28, 2019
·
4 min read
Biotech Beach

Amgen Announces New Clinical Data Evaluating Novel Investigational KRAS(G12C) Inhibitor In Patients With Solid Tumors At ESMO 2019

Responses Seen in Multiple Tumor Types With KRAS G12C Mutation

September 28, 2019
·
11 min read
Drug Development

Adjuvant Treatment with Opdivo (nivolumab) Continues to Demonstrate Extended Recurrence-Free Survival at Three Years in Resected High-Risk Melanoma Patients

Three-year analysis from Phase 3 CheckMate -238 study represents longest follow-up of any PD-1 inhibitor in the adjuvant melanoma setting

September 28, 2019
·
45 min read
Pharm Country

Bayer Announces Updated Analysis for Vitrakvi® (larotrectinib) Demonstrating High Response Rate and Duration of Response of Nearly Three Years in Adults and Children with TRK Fusion Cancer

New data cut-off confirmed Vitrakvi is the only TRK inhibitor to demonstrate an overall response rate (ORR) of nearly 80 percent in an expanded population of more than 150 patients, including an ORR of 75 percent in patients with brain metastases

September 28, 2019
·
9 min read
Drug Development

Tolero Pharmaceuticals Presents Preliminary Findings from Phase 1 Study Evaluating Investigational Agent TP-0903 in Patients with Advanced Solid Tumors at ESMO 2019

Tolero Pharmaceuticals, Inc. presented new data from the ongoing Phase 1 study evaluating the maximum tolerated dose of the oral investigational agent TP-0903, an AXL receptor tyrosine kinase inhibitor, in patients with advanced solid tumors.

September 28, 2019
·
5 min read
Drug Development

ESSA Pharma Presents New Data on EPI-7386 at the European Society of Medical Oncology (ESMO) 2019 Congress

ESSA Pharma Inc. presented new preclinical data on ESSA’s lead Investigational New Drug candidate at the 2019 American Urological Association Annual Meeting.

September 28, 2019
·
5 min read
Drug Development

Bicycle Therapeutics Announces Presentation of Updated Data from Phase I/IIa Trial Evaluating BT1718 in Patients with Advanced Solid Tumors at ESMO 2019 Annual Congress

Bicycle Therapeutics plc announced the presentation of updated data from a Phase I/IIa trial conducted in collaboration with Cancer Research UK and evaluating BT1718 in an unselected group of patients with advanced solid tumors.

September 28, 2019
·
9 min read
Job Trends

ALK Sponsors Third Annual National Penicillin Allergy Day on September 28th

Day aims to increase awareness of penicillin allergies and the importance of proper diagnosis

September 28, 2019
·
3 min read
Phase 3 PRIMA trial of Zejula® (niraparib) is the first study to show a PARP inhibitor significantly improves PFS, regardless of biomarker status, when given as monotherapy in women with first-line platinum responsive advanced ovarian cancer

GlaxoSmithKline plc announced results from PRIMA (ENGOT-OV26/GOG-3012), the Phase 3 randomised, double-blind, placebo-controlled study of Zejula (niraparib) as a maintenance therapy in women with first-line ovarian cancer following a response to platinum-based chemotherapy.

September 28, 2019
·
9 min read